%0 Journal Article %A Yaqian Mao %A Wei Lin %A Junping Weng %A Gang Chen %T Epidemiological and clinical characteristics of SARS-CoV-2 and SARS-CoV: a system review %D 2020 %R 10.1101/2020.02.20.20025601 %J medRxiv %P 2020.02.20.20025601 %X Background In 2002-2003, a severe pulmonary infectious disease occurred in guangdong, China. The disease was caused by severe acute respiratory syndrome coronavirus (SARS-CoV), 17 years apart, also happen in China, and also the novel coronavirus, this epidemic has posed a significant hazard to people’s health both China and the whole world. Now the data of 2019 corona virus disease (COVID-19) are still limited. In this article, we summarized the early epidemiologic and clinical characteristics of SARS and COVID-19 in different countries. Aim to provide recommendations for the understanding and prevention of COVID-19.Methods By searching pubmed, we analyzed and compared the typical cases of SARS and COVID-19 in different countries in the early stage of the outbreak. Clinical records, laboratory results, imageological diagnosis and pathologic condition were retrospectively reviewed for these cases. This paper adopts the method of descriptive statistics and tables and graphs.Findings Six SARS-related articles (N=337 participants) and 12 COVID-19-related articles (N=50,096 participants) were eligible for this systematic review. Fever, cough and Malaise/Fatigue were the most common symptoms in SARS and COVID-19. But in general, the clinical symptoms and signs of COVID-19 were not obvious. Compared with SARS, COVID-19 was transmitted in a more diverse way, from person to person, asymptomatic infected people and possible fecal-oral transmission, created the conditions for a large-scale spread. The mortality rates of SARS and COVID-19 were (7.7%) and (2.2%) respectively, but the overall infection rate of healthcare worker of COVID-19 (3.9%) was lower than that of SARS (40.0%). We also summarize the current reports on the pathology of COVID-19, we found that the pathological features of COVID-19 have greatly similar with SARS, which manifested as acute respiratory distress syndrome (ARDS).Interpretation The epidemiological and clinical characteristics of SARS and COVID-19 in China are very similar, but also difference. In general, COVID-19 is transmitted in more diverse ways and is more infectious, so the early recognition of disease by healthcare worker and patient is very important. Active and effective isolation measures for suspected and close contacts are necessary.Funding None.Research in contextEvidence before this studyEvidence before this studyThe kind of pneumonia caused by the 2019 novel coronavirus disease (COVID-19) is a highly infectious disease, that WHO has declared it as a global public health emergency.With the deepening understanding of COVID-19 infection and the accumulation of diagnosis and treatment experience, the epidemiological and clinical characteristics of COVID-19 have changed constantly, but our understanding of COVID-19 remained to be elucidated, especially in pathology.Added value of this studyAdded value of this studyCompared with SARS, we found COVID-19 was transmitted in a more diverse way, Fever, cough and Malaise/Fatigue were the most common symptoms in both dieases. But in general, the clinical symptoms and signs of COVID-19 were not obvious.We found that the pathological features of COVID-19 greatly resemble those seen in SARS, their features associated with acute respiratory distress syndrome.Implications of all the available evidenceImplications of all the available evidenceThis paper summarized the latest epidemiological changes, clinical manifestations and pathological examination of COVID-19, aim to make the majority of medical workers have a more comprehensive understanding, and improve the level of prevention, control, diagnosis and treatment and improve the prognosis of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article. %U https://www.medrxiv.org/content/medrxiv/early/2020/02/25/2020.02.20.20025601.full.pdf